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Although missense mutations of the von Hippel-
Lindau disease (VHL) gene are the most common
germline mutation underlying this heritable cancer
syndrome, the mechanism of tumorigenesis is
unknown. We found a quantitative reduction of
missense mutant VHL protein (pVHL) in tumors asso-
ciated with physiologic mRNA expression. Although
mutant pVHL is unstable and degraded contempo-
rarily with translation, it retains its E3 ligase function,
including hypoxia-inducible factor degradation. The
premature pVHL degradation is due to misfolding
and imbalance of chaperonin binding. Histone de-
acetylase inhibitors (HDACIs) can modulate this
pathway by inhibiting the HDAC-Hsp90 chaperone
axis, stabilizing pVHL, and restoring activity compa-
rable to wild-type protein, both in vitro and in animal
models. Furthermore, HDACI-mediated stabilization
ofmissense pVHL significantly attenuates the growth
of 786-O rodent tumor model. These findings provide
direct biological insight into VHL-associated tumors
and elucidate a treatment paradigm for VHL.
INTRODUCTION
Germline von Hippel-Lindau disease (VHL) gene mutations
underlie VHL pathogenesis (Latif et al., 1993; Richard et al.,
2012; Seizinger et al., 1988; Shen and Kaelin, 2012). VHL protein
(pVHL) is an E3 ligase in the VCB-Cul2 complex (Okuda et al.,
2001), which is responsible for binding, targeting, and degrading
hypoxia-inducible factor (HIF)-1a/HIF-2a via the ubiquitin pro-
teasome pathway (Cockman et al., 2000; Maxwell et al., 1999;
Ohh et al., 2000). Reduction or absence of pVHL function leads
to a marked and unregulated amplification in HIF activity under
nonhypoxic conditions, which is oncogenic via activation of
multiple signaling pathways underlying cell proliferation, survival,
motility, angiogenesis, and metabolism (Cockman et al., 2000;
Krieg et al., 2000; Maxwell et al., 1999; Ohh et al., 2000; Tani-
moto et al., 2000). The precise mechanism underlying loss of
pVHL function is not known.
Emerging evidence indicates abnormal protein conformation
associated with germline mutations in heritable disorders may52 Cell Reports 3, 52–59, January 31, 2013 ª2013 The Authorslead to abnormal chaperone protein recognition and accelerated
degradation (Lu et al., 2011; Yang et al., 2011). Specifically,
missense mutations in VHL have been shown to affect protein
conformation and folding, resulting in immediate degradation
after translation in yeast and VHL-expressing mammalian cells
(McClellan et al., 2005; Melville et al., 2003). These data suggest
mutated pVHL degradation in VHL may be controlled by the
binding of molecular chaperonin/cochaperonins, like Hsp70,
Hsp90, and TRiC/CCT (McClellan et al., 2005; Melville et al.,
2003). Altogether, these findings indicate that proteostasis alter-
ations due to VHL mutations may have a role in accelerated
pVHL mutant degradation and loss of function.
Currently, although antiangiogenic agents have been investi-
gated for treatment of renal cell carcinoma in VHL, therapy for
other VHL-associated tumors (particularly hemangioblastomas)
is surgery, which is linked to significant morbidity and mortality
(Ali et al., 2012; Jonasch et al., 2011; Lonser et al., 2003).
Consequently, new noninvasive, syndrome-specific therapies
are needed. Better understanding of the precise mechanism
underlying VHL-associated oncogenesis is needed to develop
these targeted treatments. We demonstrate that missense
mutations in VHL cause significant quantitative intracellular
reduction of functional pVHL due to rapid degradation.
Chaperonin and cochaperonins are involved with the rapid
degradation of mutant VHL protein. Proteostasis modulators
can prolong mutant protein half-life and ameliorate tumor
progression.
RESULTS AND DISCUSSION
pVHL in VHL-Derived Tumors
Prior studies have demonstrated that loss of pVHL function in
VHL-associated tumors underlies oncogenesis (Iliopoulos
et al., 1995; Lubensky et al., 1996; Mehta et al., 2008). To begin
to establish the cause of pVHL loss of function, we initially exam-
ined pVHL levels in VHL-associated tumors. VHL-associated
tumors have significantly reduced or absent pVHL expression
(hemangioblastomas = 14; renal cell carcinomas = 3) by immu-
nofluorescence, including tumors with missense, frameshift, or
deletions of VHL (Figure 1A). Compared to controls, a 65% to
96% decrease in pVHL expression was found in missense
VHL-associated tumors (Figure 1B). Alternatively, CD31,
a marker for endothelium associated with deactivation of VHL
(Wizigmann-Voos et al., 1995), was increased 90% to 890%.
Moreover, consistent with an association between pVHL level
Figure 1. Quantitative Loss of pVHL with Intact mRNA Expression of VHL in Hemangioblastoma and RCC
(A) Immunofluorescence staining for VHL (green) and CD31 (red) in VHL-associated hemangioblastoma and RCC specimen (scale bar, 50 microns).
(B) Quantitative analysis of VHL and CD31 protein expression in normal brain specimen (n = 3), hemangioblastoma (n = 3), and RCC (n = 3) with missense VHL
mutations, showing increased CD31 expression in hemangioblastomas and RCC.
(C) Quantification of CD31 immunofluorescence compared to VHL immunofluorescence signal of patient samples (R2 = 0.8).
(D) The total number of central nervous system VHL-associated hemangioblastomas found on magnetic resonance imaging was inversely related to pVHL
immunofluorescence (R2 = 0.9).
(E) Western blot analysis of pVHL from microdissected VHL-associated hemangioblastomas. Quantitative real-time PCR for VHL mRNA expression demon-
strating maintenance of VHL mRNA in VHL-associated hemangioblastomas and RCCs.
(F) Real-time PCR quantification of hypoxia-related gene expression in tumor specimens further confirming that classic hypoxia-related genes are upregulated in
VHL-associated tumors.
Data expressed as mean ± SEM; n = 6 fields/group for (C) and (D); and n = 3 real-time PCR reactions/group for (F).and expression of VHL pathobiology, pVHL level was inversely
related to CD31 expression (R2 = 0.8; Figure 1C) and central
nervous system hemangioblastoma development in patients(R2 = 0.9; Figure 1D). Western blot analysis also confirmed the
absence of pVHL in all VHL-associated tumor specimens
(Figure 1E).Cell Reports 3, 52–59, January 31, 2013 ª2013 The Authors 53
Expression of VHL mRNA in Tumors
To determine if the quantitative decrease in pVHL was the
result of abnormal mRNA expression, we measured VHL
mRNA transcript levels in microdissected hemangioblastomas
(n = 5) and RCCs (n = 3) from VHL patients harboring germline
missense mutations, which are the most common VHL germ-
line mutation (Maher and Kaelin, 1997; Stolle et al., 1998).
VHL mRNA was similarly expressed in the tumors and normal
brain (Figure 1E). Consistent with lack of pVHL function,
hypoxia-associated gene expression was profoundly upregu-
lated. Genes, including EPO (increased 131 to 643%), EDN1
(increased 200 to 1126%), VEGFa (increased 37 to 227%),
and GLUT1 (increased by 206 to 2255%) were markedly
elevated in VHL-associated tumors compared to control (Fig-
ure 1F), consistent with the abnormal hypoxia response seen
with constitutively activated HIF-signaling in VHL (Keith et al.,
2012).
Stability of pVHL in Tumor-Derived Mutants
Because maintenance of physiologic levels of VHL mRNA
expression indicated that the quantitative loss of pVHL occurs
at the translational level or is determined by rate of degrada-
tion, we hypothesized that changes in protein stability underlie
the loss of protein amount/function found in VHL-associated
hemangioblastomas (McClellan et al., 2005). To test this
theory, we examined mutant and wild-type pVHL stability
in vitro. Because missense mutations are the most frequent
genetic changes in VHL-associated tumors, we analyzed
pVHL kinetics in vitro from 3 VHL missense mutations (S68W,
Y112N, and A149S) (Atuk et al., 1998; Be´roud et al., 2000;
Nordstrom-O’Brien et al., 2010) found in VHL patients with
either of the major forms of VHL, Type 1 (Y112N), or Type 2
(S68W and A149S) VHL (Lonser et al., 2003; van der Harst
et al., 1998).
S68W, Y112N, and A149S missense mutations were trans-
fected into the VHL-deficient cell line 786-O. All pVHL mutants
were successfully synthesized as full-length proteins. Protein
expression between mutant and wild-type pVHL was not
different. To assess pVHL stability, we used cycloheximide
(CHX)-mediated pulse chase assay and western blot analysis
(Figure 2A). Quantitative analysis revealed that wild-type
pVHL has a half-life of 3.8 hr in physiologic conditions, but
tumor-derived mutant protein (DVHL-S68W, DVHL-Y112N,
and DVHL-A149S) half-life was significantly reduced to 1.2,
1.9, and 0.6 hr, respectively (Figure 2B). This is consistent
with the previous finding that pVHL with Type 1 VHL
(surface-type) mutations exhibit longer half-life than Type 2
VHL (deep-type) mutations (Ong et al., 2007).
To confirm these results, we utilized [35S]-methionine-medi-
ated pulse-chase analysis to the same missense mutant
pVHL. Autoradiography confirmed that the mutants were
synthesized in full length. Consistent with the prior results,
newly synthesized mutant proteins exhibited significantly
shortened half-life (0.3 hr) compared with wild-type pVHL
(2 hr) due to immediate degradation after synthesis (Figure 2C).
Consequently, the fundamental loss of mutant pVHL stability,
due to reduction in half-life, was confirmed by liquid scintilla-
tion on [35S] radioactivity (Figure 2D).54 Cell Reports 3, 52–59, January 31, 2013 ª2013 The AuthorsFunctional Capacity of Mutant pVHL
Although the previous findings indicated that there is a quantita-
tive loss of pVHL in VHL-associated tumors and that reduced
protein stability underlies this reduction in protein, it was unclear
if the intrinsic function of the missense mutant pVHL is also
impacted, further impairing its E3 ligase activity. To determine
whether tumor-derived pVHL mutants exhibit impaired E3
ligase activity, we studied HIF1a degradation through transfec-
tions of both wild-type and missense VHL in 786-O cells (HA-
HIF1a-786-O stable transfects; Figure 2E) (Gnarra et al., 1994;
Iliopoulos et al., 1995).
Western blot analysis revealed that HIF1a is efficiently
degraded upon transfection of wild-type or missense VHL, indi-
cating that missense pVHL can effectively degrade HIF1a in
nonhypoxic conditions. To verify that missense pVHL retains
E3 ligase intrinsic function and proper binding capacity to
HIF1/2a, immunoprecipitation was performed both for VHL and
HIF1a. Western blot analysis of the immunoprecipitate
confirmed that the three missense mutants exhibit similar
binding capacity and E3 ligase activity as wild-type pVHL, which
was demonstrated by HIF1a ubiquitination (Figure 2F). Binding
of missense pVHL products was also confirmed by an ex vivo
peptide binding assay that showed mutant pVHL had a similar
affinity to HIF-derived peptide as wild-type pVHL (Figure 2G).
We further confirmed intact missense pVHL function via
measuring luciferase activity driven by hypoxia regulated
element (HRE) promoter. Upon cotransfection of wild-type or
missense VHL and HRE-luciferase plasmid into HA-HI-
F1a-786-O cells, HRE transcription activity was reduced by
91% in wild-type VHL, whereas tumorigenic missense VHL
mutants transfection reduced HRE transcription activity 54%
to 81% (Figure 2H). Changes in transcription activity due
to VHL mutant reintroduction were further established by
measuring hypoxia-related gene expression using quantitative
real-time PCR assay (Figure 2I) that revealed reduction of
EDN1 (31 to 77%), EPO (22 to 52%), VEGFA (56 to 89%), and
GLUT1 (48 to 58%) mRNA expression in wild-type and missense
mutant VHL. Our result confirmed the previous finding that
pVHL with missense mutation retains partial functional capacity
as an E3 ligase (Chung et al., 2006; Li et al., 2007).
pVHL Degradation
To define the mechanism underlying rapid turnover of mutant
pVHL, we investigated the impact of protein quality control/
degradation pathways on mutant and wild-type pVHL. Specifi-
cally, cotranslational degradation of VHL mutants in the nascent
peptide stage is dependent on a quality control system that
includes protein-folding machinery and chaperonin/cochapero-
nins (Feldman et al., 1999). To elucidate the critical molecules
that direct pVHL mutant into degradation, we performed immu-
noprecipitation assays to detect chaperonin binding tomissense
mutant pVHL (Figure 3A). Wild-type pVHL bound robustly to
Hsp70 and TCP1 but significantly less to Hsp90. Alternatively,
missense mutant pVHL (DVHL-S68W, DVHL-Y112N, and
DVHL-A149S) exhibited decreased physical interaction to
Hsp70 and TCP1 but increased affinity to Hsp90, consistent
with abnormalities in chaperonin binding contributing to rapid
degradation (McClellan et al., 2005). Involvement of Hsp70/90
Figure 2. Mutant pVHL Maintains Intrinsic Function but Has Shortened Half-Life
(A) Cycloheximide (CHX) treatment of wild-type and pVHL mutants at 0, 1, 2, and 4 hr demonstrates rapid degradation of mutant pVHL versus wild-type.
(B) Calculation of protein degradation kinetic of wild-type and pVHL mutants yielded pVHL mutants have shortened half-life.
(C) Radioactive [35S] pulse chase assay for DVHL-A149S mutant and wild-type at 0, 0.5, 1, 2, and 4 hr, confirming that pVHL have shortened half-life compared
to wild-type.
(D) Scintillation analysis of [35S]-labeled VHL demonstrating fundamental loss of pVHL stability in mutants compared to wild-type.
(E) Westernblot for steady-state-expressedHA-taggedHIF1awithpVHLmutant reintroductiondemonstrating successful degradationofHA-HIF1abypVHLmutants.
(F) Forward and reverse immunoprecipitation for HA-HIF1a binding with pVHL mutants demonstrates similar binding affinities of pVHL as compared to wild-type
VHL to HIF1a.
(G) Autoradiography and radioactive scintillation for ex vivo binding of pVHL mutants to HIF2a-derived peptides demonstrating similar affinity of mutant pVHL
compared with wild-type control (IVT VHL - in vitro translation of pVHL).
(H) Luciferase assay for transcriptional activity of HRE-luciferase in 786-O cells with VHLmutant reintroduction reveals decreasedHRE-luciferase activity in those
with wild-type and missense VHL; thus, missense VHL suppress HIF1a and its target genes.
(I) Quantitative real-time PCR of hypoxia-related genes in 786-O cells with VHL mutant reintroduction further demonstrates missense VHL abilities to regulate
HIF1a target genes (GLUT1, EDN1, EPO, and VEGFA) similarly to wild-type VHL.
Data expressed as mean ± SEM; n = 3 radioactive scintillation for (G); n = 3 luciferase reaction/group for (H); and n = 3 real-time PCR reactions/group for (I).appears critical for mutant pVHL degradation because siRNA
silencing on Hsp70/90-organizing protein STIP1 elongates
DVHL-Y112N protein half-life (Figure 3B).
Modulation of Missense pVHL Stability
The chaperonin system role in rapid degradation of mutant pVHL
highlighted a potential therapeutic strategy that exploits pharma-
cologic manipulation of this protein homeostatic pathway.
Specifically, histone deacetylase inhibitors (HDACIs) can actively
modulate protein folding and degradation machinery by target-
ing chaperone and chaperonin system. SAHA and LB-205 are
HDACIs that affect molecular chaperone HSP90 binding to
proteins, including mutant pVHL. SAHA, a Food and DrugAdministration-approved small molecular weight HDACI, inhibits
HDAC by binding the zinc atom in its catalytic site (Finnin et al.,
1999). Similarly, LB-205 is a new small-molecule HDACI that also
exploits a zinc-binding moiety that inhibits HDACs but has
a longer half-life than SAHA (SAHA half-life, 4 to 8 hr; LB-205
half-life, 12 hr) (Lu et al., 2011).
To determine if HDACIs reduce mutant pVHL degradation and
minimize HIF1a-related gene expression, we examined the
protein expression of the missense VHL products (DVHL-
S68W, DVHL-Y112N, and DVHL-A149S) in treated and
untreated 786-O cells. We found that Hsp90 affinity to VHL
mutants dramatically decreased with SAHA or LB-205 treatment
(Figure 3C). To evaluate the impact of HDACIs on pVHL stability,Cell Reports 3, 52–59, January 31, 2013 ª2013 The Authors 55
Figure 3. Increased Survival VHL Mutant Protein after Treatment with HDAC Inhibitors and Reduction of Tumor Growth Corresponds to
Increased Expression of VHL
(A) Immunoprecipitation assay for chaperonin binding to mutant VHL protein demonstrating loss of Hsp70 and TCP1 but increased Hsp90 binding.
(B) Western blots for protein stability change of DVHL-Y112N with STIP1 RNA interference, confirming the role of STIP1 in pVHL degradation pathway.
(C) Immunoprecipitation assay for changes in chaperonin binding to mutant VHL protein after LB-205 or SAHA treatment, demonstrating that treatment with
HDACI can alter chaperonin binding to pVHL.
(D) Western blot for DVHL-Y112N stability with proteostasis regulator treatments.
(E) Quantification of protein half-life, exhibiting treatment with HDACI prolongs pVHL half-life.
(F) Tumor growth of stably transfected DVHL-A149S 786-O (107) cells subcutaneous after 3 weeks treatment with vehicle in comparison to parental control,
confirming that the presence of pVHL can inhibit tumor growth (p < 0.0001).
(G) Tumor growth of stably transfected DVHL-A149S 786-O (107) cells subcutaneous after reaching 300 mm3 and then treated with DMSO, SAHA, or LB-205;
HDACI halted tumor progression (p < 0.0001).
(H) Western blots for DVHL-A149S from tumors at the end of treatment, increased VHL expression by addition of HDACI correlated to attenuated tumor
progression.
Data expressed as mean ± SEM; n = 5 mice/group for (F); and n = 3 to 5 mice/group for (G).we performed protein half-life measurements based on CHX
treatment (Figure 3D). Consistent with the in vitro results, mutant
pVHL was rapidly degraded in physiologic conditions. LB-205
and SAHA stabilized the protein within the same CHX assay,
increasing the half-life of mutant pVHL to 2.5 and 10.2 hr, respec-
tively (Figure 3E).
Effect of HDACI on Tumor Growth
To determine if introduction of stable missense pVHL in tumor
cells would have an effect on tumor growth, we subcutaneously56 Cell Reports 3, 52–59, January 31, 2013 ª2013 The Authorsinjected stably transfected missense DVHL-A149S 786-O and
empty vector cells into athymic nu/nu mice. Consistent with
the in vitro data demonstrating maintenance of intrinsic function
of missense mutant pVHL and previous data examining the
effect of a VHL missense mutation in 786-O cells (Hansen
et al., 2002), reintroduction of steady-state levels of missense
VHL inhibited tumor growth in vivo (p < 0.0001) compared to
empty vector 786-O parental control cells. Specifically, there
was 99% reduction in tumor growth with introduction of
missense VHL compared to control (Figure 3F).
To determine if HDACI would have similar effects on stability
of missense pVHL products in vivo, NOD/SCID IL2Rgamma
null mice with stably transfected missense DVHL-A149S 786-
O tumors were treated with HDACIs (SAHA and LB-205).
Treated mice had a 57% and 61% reduction in tumor growth
(SAHA and LB-205, respectively) compared to vehicle-treated
DVHL-A149S 786-O tumors (p < 0.0001; Figure 3G). The lack
of a significant difference between SAHA and LB-205 for the
effective amelioration of tumor progression (p > 0.05) indicates
that single daily dosing may be an effective strategy to inhibit
hemangioblastoma growth. SAHA and LB-205 enable the main-
tenance of sufficient VHL enzyme activity to curtail tumor
progression (Dollfus et al., 2002; Rini et al., 2009; Wanebo
et al., 2003). Expression of the mutant protein was verified by
western blot of excised tumors, demonstrating quantitative
increases in the missense mutant pVHL with treatment of
SAHA and LB-205 (Figure 3H).
These findings provide critical insights into understanding VHL
pathogenesis and treatment. Specifically, protein degradation
pathways that reduce missense mutant pVHL half-life appear
to underlie the reduction in intracellular pVHL activity/amount.
Moreover, the findings also increase the basic understanding
of the nature of the primary biochemical abnormality with
different VHL mutations and help to define a possible mecha-
nism to explain the substantial phenotypic heterogeneity that
characterizes the VHL disease. Therapeutic modification of the
protease pathways involved in degradation of missense pVHL
mutants with intrinsic E3 ligase function may provide new
strategies for treatment of VHL.
EXPERIMENTAL PROCEDURES
VHL Tumor Samples
Tissues, imaging, and clinical data were collected under institute-approved
protocols (National Institutes of Health [NIH] #03-N-0164 and #00-N-0147).
Tissue samples included VHL-associated hemangioblastomas and RCC, as
well as normal brain. Dissection of tissues has been detailed previously
(Zhuang et al., 1995).
Protein Extraction
Cell pellet or microdissected tissue specimens were extracted for protein in
RIPA lysis buffer (Thermo Fischer Scientific, Rockford, IL, USA) with Halt
Protease Inhibitor (Thermo Fischer Scientific) and purified through centrifuge.
The Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA, USA) was used to
quantify protein in the supernatant.
Western Blot
Protein samples were resolved on 4%–15% Bis-Tris gels (Invitrogen,
Carlsbad, CA, USA) and placed on polyvinylidene fluoride membranes
(Millipore, Billerica, MA, USA). Membranes were probed using antibodies
against b-Actin (1:2,000; Sigma-Aldrich, St. Louis, MO, USA), FLAG (1:2,000;
Origene, Rockville, MD, USA), HA (1:1,000; Origene), VHL (1:500; Cell
Signaling Technology, Danvers, MA, USA), CD31 (PECAM; 1:1,000; Dako,
Glostrup, Denmark), ubiquitin (1:1,000; Cell Signaling Technology), Hsp70
(1:1,000; Sigma-Aldrich), Hsp90 (1:1,000; Cell Signaling Technology),
and TCP1 (1:1,000; Sigma-Aldrich). Horseradish-peroxidase-conjugated
secondary antibodies (species-specific) were visualized by enhanced chemi-
luminescence substrate (SuperSignal; Thermo Fischer Scientific).
Immunoprecipitation
Immunoprecipitation was performed by applying 200 mg of whole-cell lysate to
Dynabeads (Invitrogen) preincubated with monoclonal antibodies againstFLAG or HA (1:200; Origene). Stringent washing and elutions were performed
per the manufacturer’s protocol.
Immunofluorescence Analysis
Frozen sections from tumor specimen were fixed and labeled overnight with
primary antibodies against VHL (1:50; Cell Signaling Technology) and CD31
antibody (1:200; Dako). Cell nuclei were counterstained (Hoechst 33342;
Invitrogen). Immunofluorescence was analyzed by confocal microscopy.
Real-Time PCR
Gene expression was measured by PCR on the Eco Real-time PCR Platform
(Illumina, San Diego, CA, USA). PCR was performed with primer sets for
VHL, EPO, EDN1, GLUT1, and VEGFA (GAPDH internal control; QIAGEN,
Hilden, Germany) using Power SYBR Green PCR Master Mix (Applied
Biosystems, Carlsbad, CA, USA).
Cell Culture and Transfection
The VHL-deficient cell line 786-O (ATCC) was transfected with VHL or HIF1/2
vectors by using Xtremegene 9 transfection reagent (Roche, Indianapolis, IN,
USA). Stable transfection was established through a 10-day G418 (0.5 mg/ml)
selection, followed by serial dilution and western blot verification. Cells were
exposed to 10 mg/ml CHX for protein stability measurement.
Mutagenesis and Cloning
Using site-directed mutagenesis kit (Agilent, Santa Clara, CA, USA), VHL
site-specific mutations were generated. Three known VHL patient missense
mutations were selected (Be´roud et al., 2000; Gallou et al., 1999). Mutants
and wild-type VHL were generated and sequenced in pCMV6-Entry vectors
(Origene). HA-HIF1alpha-pcDNA3 and HA-HIF2alpha-pcDNA3 were gifts of
Dr. William Kaelin (Addgene plasmid #18949 and #18950).
35S Metabolic Labeling and Pulse Chase Assessment
Pulse chasewith [35S]-methionine was performed as previously describedwith
modifications (McClellan et al., 2005). Seven hundred thousand 786-O cells
were transfected with VHL vectors 12 hr before labeling. pVHL was immuno-
precipitated with monoclonal FLAG antibody (Origene) using 200 mg from
whole-cell lysate.
In Vivo Tumor Model
Five-week-old athymic mice (Taconic, Hudson, NY, USA) or NOD/SCID IL2R-
gamma null mice (The Jackson Laboratory, Bar Harbor, ME, USA) were in-
jected with 107 cells subcutaneously into the flanks. Tested clonal lines
included 786-O and 786-O stably transfected with missense DVHL-A149S
lines. Tumor volumes were assessed bymeasuring width and length (volume =
width2 3 length) with digital calipers. Daily treatment with SAHA (15 mg/kg)
and LB-205 (15 mg/kg) were given intraperitoneally after reaching 300 mm3.
Tumors were harvested at 10 days after treatments.
LICENSING INFORMATION
This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-No Derivative Works License, which
permits non-commercial use, distribution, and reproduction in any medium,
provided the original author and source are credited.
ACKNOWLEDGMENTS
This research was supported by the Intramural Research Program of the
National Institute of Neurological Disorders and Stroke (NINDS) and a cooper-
ative research and development agreement between NINDS and Lixte
Biotechnology Holdings, Inc.
Received: July 7, 2012
Revised: November 30, 2012
Accepted: December 13, 2012
Published: January 10, 2013Cell Reports 3, 52–59, January 31, 2013 ª2013 The Authors 57
REFERENCES
Ali, T., Kandil, D., and Piperdi, B. (2012). Long-term disease control with
sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET)
associated with Von Hippel-Lindau syndrome (VHL). Pancreas 41, 492–493.
Atuk, N.O., Stolle, C., Owen, J.A., Jr., Carpenter, J.T., and Vance, M.L. (1998).
Pheochromocytoma in von Hippel-Lindau disease: clinical presentation and
mutation analysis in a large, multigenerational kindred. J. Clin. Endocrinol.
Metab. 83, 117–120.
Be´roud, C., Collod-Be´roud, G., Boileau, C., Soussi, T., and Junien, C. (2000).
UMD (Universal mutation database): a generic software to build and analyze
locus-specific databases. Hum. Mutat. 15, 86–94.
Chung, J., Roberts, A.M., Chow, J., Coady-Osberg, N., and Ohh, M. (2006).
Homotypic association between tumour-associated VHL proteins leads to
the restoration of HIF pathway. Oncogene 25, 3079–3083.
Cockman, M.E., Masson, N., Mole, D.R., Jaakkola, P., Chang, G.W., Clifford,
S.C., Maher, E.R., Pugh, C.W., Ratcliffe, P.J., and Maxwell, P.H. (2000).
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-
Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733–25741.
Dollfus, H., Massin, P., Taupin, P., Nemeth, C., Amara, S., Giraud, S., Be´roud,
C., Dureau, P., Gaudric, A., Landais, P., and Richard, S. (2002). Retinal heman-
gioblastoma in von Hippel-Lindau disease: a clinical and molecular study.
Invest. Ophthalmol. Vis. Sci. 43, 3067–3074.
Feldman, D.E., Thulasiraman, V., Ferreyra, R.G., and Frydman, J. (1999).
Formation of the VHL-elongin BC tumor suppressor complex is mediated by
the chaperonin TRiC. Mol. Cell 4, 1051–1061.
Finnin, M.S., Donigian, J.R., Cohen, A., Richon, V.M., Rifkind, R.A.,
Marks, P.A., Breslow, R., and Pavletich, N.P. (1999). Structures of a histone
deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401,
188–193.
Gallou, C., Joly, D., Me´jean, A., Staroz, F., Martin, N., Tarlet, G., Orfanelli, M.T.,
Bouvier, R., Droz, D., Chre´tien, Y., et al. (1999). Mutations of the VHL gene in
sporadic renal cell carcinoma: definition of a risk factor for VHL patients to
develop an RCC. Hum. Mutat. 13, 464–475.
Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S.,
Chen, F., Duh, F.M., et al. (1994). Mutations of the VHL tumour suppressor
gene in renal carcinoma. Nat. Genet. 7, 85–90.
Hansen, W.J., Ohh, M., Moslehi, J., Kondo, K., Kaelin, W.G., and Welch, W.J.
(2002). Diverse effects of mutations in exon II of the von Hippel-Lindau
(VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic
chaperonin and pVHL-dependent ubiquitin ligase activity. Mol. Cell. Biol. 22,
1947–1960.
Iliopoulos, O., Kibel, A., Gray, S., and Kaelin,W.G., Jr. (1995). Tumour suppres-
sion by the human von Hippel-Lindau gene product. Nat. Med. 1, 822–826.
Jonasch, E., McCutcheon, I.E., Waguespack, S.G., Wen, S., Davis, D.W.,
Smith, L.A., Tannir, N.M., Gombos, D.S., Fuller, G.N., and Matin, S.F. (2011).
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
Ann. Oncol. 22, 2661–2666.
Keith, B., Johnson, R.S., and Simon, M.C. (2012). HIF1a and HIF2a:
sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer
12, 9–22.
Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., and Plate, K.H. (2000).
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under
normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor
suppressor gene loss of function. Oncogene 19, 5435–5443.
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.M., Orcutt, M.L., Stackhouse, T.,
Kuzmin, I., Modi, W., Geil, L., et al. (1993). Identification of the von Hippel-Lin-
dau disease tumor suppressor gene. Science 260, 1317–1320.
Li, L., Zhang, L., Zhang, X., Yan, Q., Minamishima, Y.A., Olumi, A.F., Mao, M.,
Bartz, S., and Kaelin, W.G., Jr. (2007). Hypoxia-inducible factor linked to differ-
ential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol.
Cell. Biol. 27, 5381–5392.58 Cell Reports 3, 52–59, January 31, 2013 ª2013 The AuthorsLonser, R.R., Glenn, G.M., Walther, M., Chew, E.Y., Libutti, S.K., Linehan,
W.M., and Oldfield, E.H. (2003). von Hippel-Lindau disease. Lancet 361,
2059–2067.
Lu, J., Yang, C., Chen, M., Ye, D.Y., Lonser, R.R., Brady, R.O., and Zhuang, Z.
(2011). Histone deacetylase inhibitors prevent the degradation and restore the
activity of glucocerebrosidase in Gaucher disease. Proc. Natl. Acad. Sci. USA
108, 21200–21205.
Lubensky, I.A., Gnarra, J.R., Bertheau, P., Walther, M.M., Linehan, W.M., and
Zhuang, Z. (1996). Allelic deletions of the VHL gene detected in multiple micro-
scopic clear cell renal lesions in von Hippel-Lindau disease patients. Am. J.
Pathol. 149, 2089–2094.
Maher, E.R., and Kaelin,W.G., Jr. (1997). von Hippel-Lindau disease.Medicine
(Baltimore) 76, 381–391.
Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cock-
man, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J. (1999).
The tumour suppressor protein VHL targets hypoxia-inducible factors for
oxygen-dependent proteolysis. Nature 399, 271–275.
McClellan, A.J., Scott, M.D., and Frydman, J. (2005). Folding and quality
control of the VHL tumor suppressor proceed through distinct chaperone
pathways. Cell 121, 739–748.
Mehta, G.U., Shively, S.B., Duong, H., Tran, M.G., Moncrief, T.J., Smith, J.H.,
Li, J., Edwards, N.A., Lonser, R.R., Zhuang, Z., et al. (2008). Progression of
epididymal maldevelopment into hamartoma-like neoplasia in VHL disease.
Neoplasia 10, 1146–1153.
Melville, M.W., McClellan, A.J., Meyer, A.S., Darveau, A., and Frydman, J.
(2003). The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to
assemble the von Hippel-Lindau tumor suppressor complex. Mol. Cell. Biol.
23, 3141–3151.
Nordstrom-O’Brien, M., van der Luijt, R.B., van Rooijen, E., van denOuweland,
A.M., Majoor-Krakauer, D.F., Lolkema, M.P., van Brussel, A., Voest, E.E., and
Giles, R.H. (2010). Genetic analysis of von Hippel-Lindau disease. Hum.Mutat.
31, 521–537.
Ohh, M., Park, C.W., Ivan, M., Hoffman, M.A., Kim, T.Y., Huang, L.E., Pavle-
tich, N., Chau, V., and Kaelin, W.G. (2000). Ubiquitination of hypoxia-inducible
factor requires direct binding to the beta-domain of the von Hippel-Lindau
protein. Nat. Cell Biol. 2, 423–427.
Okuda, H., Saitoh, K., Hirai, S., Iwai, K., Takaki, Y., Baba,M., Minato, N., Ohno,
S., and Shuin, T. (2001). The von Hippel-Lindau tumor suppressor protein
mediates ubiquitination of activated atypical protein kinase C. J. Biol. Chem.
276, 43611–43617.
Ong, K.R., Woodward, E.R., Killick, P., Lim, C., Macdonald, F., and Maher,
E.R. (2007). Genotype-phenotype correlations in von Hippel-Lindau disease.
Hum. Mutat. 28, 143–149.
Richard, S., Gardie, B., Couve´, S., and Gad, S. (2012). Von Hippel-Lindau: how
a rare disease illuminates cancer biology. Semin. Cancer Biol. Published online
May 30, 2012.
Rini, B.I., Campbell, S.C., and Escudier, B. (2009). Renal cell carcinoma.
Lancet 373, 1119–1132.
Seizinger, B.R., Rouleau, G.A., Ozelius, L.J., Lane, A.H., Farmer, G.E., Lamiell,
J.M., Haines, J., Yuen, J.W., Collins, D., Majoor-Krakauer, D., et al. (1988). Von
Hippel-Lindau disease maps to the region of chromosome 3 associated with
renal cell carcinoma. Nature 332, 268–269.
Shen, C., and Kaelin,W.G., Jr. (2012). The VHL/HIF axis in clear cell renal carci-
noma. Semin. Cancer Biol. Published online June 13, 2012.
Stolle, C., Glenn, G., Zbar, B., Humphrey, J.S., Choyke, P., Walther, M., Pack,
S., Hurley, K., Andrey, C., Klausner, R., and Linehan, W.M. (1998). Improved
detection of germline mutations in the von Hippel-Lindau disease tumor
suppressor gene. Hum. Mutat. 12, 417–423.
Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L. (2000). Mechanism of
regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau
tumor suppressor protein. EMBO J. 19, 4298–4309.
van der Harst, E., de Krijger, R.R., Dinjens, W.N., Weeks, L.E., Bonjer, H.J.,
Bruining, H.A., Lamberts, S.W., and Koper, J.W. (1998). Germline mutations
in the vhl gene in patients presenting with phaeochromocytomas. Int. J.
Cancer 77, 337–340.
Wanebo, J.E., Lonser, R.R., Glenn, G.M., and Oldfield, E.H. (2003). The natural
history of hemangioblastomas of the central nervous system in patients with
von Hippel-Lindau disease. J. Neurosurg. 98, 82–94.
Wizigmann-Voos, S., Breier, G., Risau, W., and Plate, K.H. (1995). Up-regula-
tion of vascular endothelial growth factor and its receptors in von Hippel-
Lindau disease-associated and sporadic hemangioblastomas. Cancer Res.
55, 1358–1364.Yang, C., Asthagiri, A.R., Iyer, R.R., Lu, J., Xu, D.S., Ksendzovsky, A.,
Brady, R.O., Zhuang, Z., and Lonser, R.R. (2011). Missense mutations in
the NF2 gene result in the quantitative loss of merlin protein and minimally
affect protein intrinsic function. Proc. Natl. Acad. Sci. USA 108, 4980–
4985.
Zhuang, Z., Bertheau, P., Emmert-Buck, M.R., Liotta, L.A., Gnarra, J., Linehan,
W.M., and Lubensky, I.A. (1995). Amicrodissection technique for archival DNA
analysis of specific cell populations in lesions < 1 mm in size. Am. J. Pathol.
146, 620–625.Cell Reports 3, 52–59, January 31, 2013 ª2013 The Authors 59
